CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for head and neck cancer patients who Can't take chemo
Disease control OngoingThis early-stage trial tests a drug called peposertib combined with radiation therapy for people with advanced head and neck cancer who cannot take the standard chemo drug cisplatin. The goal is to find the safest dose and see if the combination helps control the cancer. About 21…
Matched conditions: CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:21 UTC
-
Can a weekly chemo schedule be gentler yet just as effective for head and neck cancer?
Disease control TerminatedThis study compares two ways of giving the chemotherapy drug cisplatin along with radiation for people with advanced head and neck cancer. One group gets a high dose every three weeks, the other gets a lower dose weekly. The goal is to see which schedule causes fewer side effects…
Matched conditions: CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 26, 2026 04:16 UTC
-
Immunotherapy after standard treatment may keep HPV throat cancer at bay
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab after standard chemoradiation helps people with HPV-positive throat cancer live longer without the cancer returning. About 636 adults with intermediate-risk, locally advanced disease will either receive nivolumab in…
Matched conditions: CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:14 UTC
-
New vaccine combo shrinks HPV throat tumors before surgery
Disease control OngoingThis study tests whether a special vaccine (PDS0101) given alone or with an immunotherapy drug (pembrolizumab) can shrink HPV-related throat tumors before surgery. About 20 adults with advanced cancer that has spread to nearby tissues or lymph nodes will receive the treatment. Th…
Matched conditions: CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC